Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VentriPoint DiagnosticsVPTDF +0.61%9 EV-to-EBIT is -8.38 as of Jul. 17, 2026. GuruFocus rates VPTDF with a GF Score™ of 9/100. The stock has 4 warning signs investors should review. Among 466 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks worse than 214592.06% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
VentriPoint Diagnostics's Enterprise Value for the quarter that ended in Dec. 2025 was $19.54 Mil.
VentriPoint Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics EV-to-EBIT Related Terms
VentriPoint Diagnostics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, VentriPoint Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's EV-to-EBIT falls into.
VentriPoint Diagnostics's current Enterprise Value is $16.43 Mil.
VentriPoint Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a EV-to-EBIT of -8.38 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is VentriPoint Diagnostics' EV-to-EBIT too high?
VentriPoint Diagnostics' current EV-to-EBIT is -8.38. Based on the distribution chart, VentriPoint Diagnostics ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, VentriPoint Diagnostics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 466 companies for EV-to-EBIT. This places VentriPoint Diagnostics in the lower half of its industry. The industry median EV-to-EBIT is 18.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.46, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current EV-to-EBIT is -8.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current EV-to-EBIT of -8.38. The current EV-to-EBIT is -8.38. VentriPoint Diagnostics' overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current EV-to-EBIT is -8.38 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
9GF Score
Get the complete analysis for VPTDF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
